My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 3
Monitoring Tumor Heterogeneity and Detecting Resistance
Experts discuss the tools available to monitor tumor heterogeneity and detect resistance, examining the reliability of current testing methods, differences in molecular testing for newly diagnosed metastatic patients vs those who have progressed, the role of liquid biopsy compared to traditional tissue biopsy, and how these test results inform risk assessment and clinical decision-making.
Video Player is loading.
Video content above is prompted by the following:
- What tools do we currently have to monitor tumor heterogeneity and detect resistance? How reliable are our current testing methods in capturing the complete resistance profile?
- How does molecular testing differ for newly diagnosed metastatic patients vs those who have progressed on prior therapies?
- What role does liquid biopsy play compared to traditional tissue biopsy in detecting heterogeneity?
- How do you incorporate these test results into your risk assessment and clinical decision-making?
